Intas Pharma has signed an exclusive licence and supply agreement with Axantia Holding for Ranibizumab (biosimilar of Lucentis).
Under the terms of this agreement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries, Intas said in a statement.
Intas has developed a biosimilar of Lucentis, which is currently under phase-III global trial for submission in major countries including EMA and the US, the statement added.